Stellate Ganglion Block for Recurrent Ventricular Arrhythmias: Mechanisms, Outcomes, and Future Directions

Stellate ganglion block (SGB) has gained attention as a potential adjunctive therapy for patients with recurrent ventricular arrhythmias, particularly in cases refractory to conventional management. This study reviews current evidence on its mechanisms, patient selection, and clinical outcomes to guide future research. A comprehensive analysis of recent literature was performed, synthesizing data on patient characteristics, procedural efficacy, and safety. Clinical studies have demonstrated encouraging short-term suppression of arrhythmias following SGB; however, the underlying patient population remains at high risk, and long-term outcomes are not yet well defined. SGB exerts its therapeutic effect through sympathetic modulation, impacting cardiac autonomic tone and electrophysiologic stability. Current research highlights the need for standardized selection criteria and procedural protocols to optimize outcomes. In conclusion, SGB represents a promising yet still investigational option for managing refractory ventricular arrhythmias, and further prospective trials are warranted to clarify its long-term efficacy, safety, and role in contemporary arrhythmia care.